Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Official title: A randomized trial of cardioprotective strategies in newly diagnosed diffuse large B-cell lymphoma and pre-existing cardiomyopathy or prior anthracycline exposure
Funded at Beth Israel Deaconess Medical Center · NIH-11402640 · Data updated 2026-11-12
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2025 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $706,054 |
| NIH project number | 5R37CA300969-02 |
| Project ID | NIH-11402640 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with newly diagnosed DLBCL at risk for heart disease or with prior anthracycline exposure or reduced heart function.
✕Less likely to help
Patients without heart risk or those who respond well to standard therapy may not rely on cardioprotective strategies.
What this research studies
The project looks at patients with diffuse large B-cell lymphoma who already have heart risk factors. It compares two strategies— dexrazoxane and liposomal doxorubicin— used alongside standard chemotherapy to see which better protects the heart without compromising cancer control. The study will enroll participants who are receiving anthracycline-containing regimens and are at risk for heart failure, monitoring heart function and cancer outcomes. Results could guide doctors on which cardioprotective approach to use for people with DLBCL and heart risk. The trial is conducted at a major Boston medical center with a clear plan for patient safety and close follow-up.
Why it matters
Potential benefit: If successful, patients could receive a clearer, more effective way to prevent heart damage during lymphoma treatment.
How similar studies have gone: Cardioprotective strategies have shown promise in other cancers, but direct comparison in DLBCL is limited, making this study novel.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Upshaw, Jenica — Beth Israel Deaconess Medical Center
- Study coordinator: Upshaw, Jenica
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
-
EBV-related lymphoma in people with immune deficiency: understanding what drives the disease
A doctor-scientist team will study a type of blood cancer linked to the Epstein-Barr virus in people with immune system problems to learn what makes it worse and how we can diagnose and treat it better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.